These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20881844)

  • 1. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.
    Hough DW; Natarajan J; Vandebosch A; Rossenu S; Kramer M; Eerdekens M
    Int Clin Psychopharmacol; 2011 Jan; 26(1):25-34. PubMed ID: 20881844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
    Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
    Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
    J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
    Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
    J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
    Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
    Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
    Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
    Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
    Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
    J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
    Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
    Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
    Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
    J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.